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1. Introduction
Dynamic regulation of genes is an important part of the cell life cycle in health and disease. The
regulation includes the variety and alteration of genome and gene expression, and the concept
such as quality of genome will be useful to predict and assess the developmental stages of the
cells, disease status and drug sensitivity. Recent technologies and worldwide sequencing
projects have revealed 26,383 annotated genes in the 2.91-Gigabase human genome [1,2]. The
main molecular functions of the annotated genes, as categorized by Gene Ontology (GO), are
enzyme,  signal  transduction,  nucleic  acid binding,  cell  adhesion,  chaperone,  cytoskeletal
structural protein, extracellular matrix, immunoglobulin, ion channel, motor, structural pro‐
tein of muscle, protooncogene, select calcium binding protein, intracellular transporter, and
transporter [1,3]. Despite a wealth of knowledge, the function of 42% of the annotated genes re‐
mains unknown [1]. When the human genome sequence was published in 2001 [1], there were
a predicted 39,114 genes, of which 59% were of unknown function. According to the Interna‐
tional Human Genome Sequencing Consortium, the number of identified genes is approxi‐
mately 32,000, of which 51% show a match within InterPro, a database that integrates diverse
information about protein families, domains, and functional sites [2-5]. In 2001, InterPro com‐
bined sequence and pattern information from four databases (PRINTS, PROSITE, Pfam, Pro‐
site  Profile);  however,  it  now  includes  information  from  an  additional  eight  databases
(SMART, ProDom, PIRSF, SUPERFAMILY, PANTHER, CATH-Gene3D, TIGRFAM, and HA‐
MAP) [2,4-16]. In [2], the InterPro entries are collapsed into 12 broad categories: cellular proc‐
esses,  metabolism,  DNA  replication/modification,  transcription/translation,  intracellular
signaling, cell–cell communication, protein folding and degradation, transport, multifunction‐
al proteins, cytoskeletal/structural, defense and immunity, and miscellaneous function. The
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rate of single nucleotide polymorphism (SNP) variation has been reported as 1 in 1250 base
pairs [1] and more than 1.4 million SNPs have been identified [2] (Table 1).
Size of the genome 2.91 Gbp [1]
Number of annotated genes 26,383 [1]
Main molecular functions of
annotated genes
enzyme, signal transduction, nucleic acid binding, cell adhesion, chaperone, cytoskeletal structural protein,
extracellular matrix, immunoglobulin, ion channel, motor, structural protein of muscle, protooncogene,
select calcium binding protein, intracellular transporter, transporter
[1]
Percentage of annotated genes
with unknown function
42% [1]
Number of hypothetical and
annotated genes
39,114 [1]
Percentage of hypothetical and
annotated genes with unknown function
59% [1]
Number of identified genes approx. 32,000 [2]
Percentage of matches with
InterPro
51% [2]
Rate of SNP variation 1/1250 bp [1]
SNPs identified more than 1.4 million [2]
Table 1. Genomic and gene characteristics revealed by the Human Genome Project.
Among the databases combined in InterPro (Table 2), PRINTS, PROSITE, and Pfam contain
protein families in which the homology between each protein is predicted by the degree of
sequence similarity [8]. The others—SMART, ProDom, PIRSF, SUPERFAMILY, PANTHER,
CATH-Gene3D, TIGRFAM, and HAMAP [4-16]—have unique characteristics and URLs,
and have been developed sharing information among each other and incorporating informa‐
tion from GO. In detail, PRINTS is a collection of diagnostic protein family “fingerprints”,
which are groups of conserved motifs, evident in multiple sequence alignments [6]; PRO‐
SITE is a protein domain database for functional characterization and annotation that con‐
sists of documentation entries describing protein domains, families, and functional sites as
well as associated patterns and profiles to identify them [7]; Pfam contains collections of
protein families, each represented by multiple sequence alignments and hidden Markov
models, available via servers in the UK, the USA, and Sweden [8]; SMART (Simple Modular
Architecture Research Tool) is an online resource for the identification and annotation of
protein domains and the analysis of protein domain architectures [9]; ProDom is a compre‐
hensive set of protein domain families generated automatically from the UniProt database
[10]; PIRSF is a classification system that reflects evolutionary relationships among full-
length proteins and domains [11]; SUPERFAMILY is a database of structural and functional
annotation for all proteins and genomes [12]; PANTHER is a classification system that clas‐
Latest Research into Quality Control436
sifies genes by their functions using published experimental evidence and evolutionary rela‐
tionships to predict function even in the absence of direct experimental evidence [13];
CATH-Gene3D is a comprehensive database of protein domain assignments for sequences
from the major sequence databases [14]; TIGRFAM is a collection of protein family defini‐
tions built to aid high-throughput annotation of specific protein functions [15]; and HAMAP
is composed of two databases: the proteome database and the family database, and of an au‐
tomatic annotation pipeline mainly focused on microbial proteomes [16]. Hidden Markov
models are usually used for the database algorithm.
Database
Name Context URL Reference
InterPro
integrative predictive models of protein families, domain and functional sites of
multiple databases such as PRINTS, PROSITE, Pfam, SMART, ProDom,
PIRSF, SUPERFAMILY, PANTHER, CATH-Gene3D, TIGRFAM, and HAMAP
http://www.ebi.ac.uk/interpro/ [4], [5]
PRINTS
a collection of diagnostic protein family
"fingerprints" which are groups of conserved motifs, evident in multiple sequence
alignments
http://www.bioinf.manchester.ac.uk/
dbbrowser/PRINTS/index.php
[6]
PROSITE
a protein domain database for functional characterization and annotation which
consists of documentation entries describing protein domains, families and functional
sites as well as associated patterns and profiles to identify them
http://prosite.expasy.org/ [7]
Pfam
a database of collection of protein families, each represented by multiple sequence
alignments and hidden Markov models, available via servers in the
UK, the USA and Sweden
http://pfam.sanger.ac.uk/http://
pfam.janelia.org/http://pfam.sbc.su.se/
[8]
SMART
an online resource for the identification and annotation of protein domains and the
analysis of protein domain architectures, of which abbreviation
is Simple Modular Architecture Research Tool
http://smart.embl.de/ [9]
ProDom
a comprehensive set of protein domain families automatically generated from the
uniProt
knowledge Database
http://prodom.prabi.fr/prodom/current/
html/home.php
[10]
PIRSF
the classification system which reflects evolutionary relationships of full-length
proteins and domains
http://pir.georgetown.edu/pirsf/ [11]
SUPERFAMILY
a database of structural and functional annotation
for all proteins and genomes
http://supfam.org/SUPERFAMILY/ [12]
PANTHER
the classification system which classifies genes by
their functions using published scientific experimental evidence and evolutionary
relationships to predict function even in the absence of direct experimental evidence
http://www.pantherdb.org/ [13]
CATH-Gene3D
a comprehensive database of protein domain assignments for sequences from the
major sequence databases
http://gene3d.biochem.ucl.ac.uk/ [14]
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Database
Name Context URL Reference
TIGRFAM
a collection of protein family definitions built to aid
in high-throughput annotation of specific protein functions
http://www.jcvi.org/cgi-bin/tigrfams/
index.cgi
[15]
HAMAP
a system which composed of two databases, the proteome database and the family
database, and of an automatic annotation pipeline
http://hamap.expasy.org/ [16]
Table 2. Database information.
2. Gene regulation
2.1. Gene markers for cancer and cancer stem cells
Several molecular markers of cancer have been identified [17]. Metastatic cancer cells can
transfer into bodily fluids through the cellular epithelia, which enables the detection of can‐
cer markers in bodily fluids such as blood plasma, urine, or saliva [17]. The different types
of cancer markers include genomic DNA point mutations, microsatellite alterations, promot‐
er hypermethylation, viral sequences, aberrant chromosomal copy number, chromosomal
translocations, deletions, or loss of heterozygosity, telomere extension, alterations in RNA or
protein expression, and mitochondrial DNA mutations [17].
Molecular markers of cancer include TP53 (encoding p53), which has been shown to be mu‐
tated in head and neck, lung, colon, pancreatic, and bladder cancer [17,18]; colon, lung,
esophagus, breast, liver, brain, reticuloendothelial tissue, and hematopoietic tissue cancers
[19]; and bladder cancer [20]. Mutation of the epidermal growth factor receptor (EGFR) gene
is an important predictive/prognostic factor for EGFR-tyrosine kinase inhibitor therapy in
non-small cell lung cancer [21]. RAS oncogene mutations have been identified in colorectal
tumors [22]. Microsatellites, which are tandem iterations of simple di-, tri-, or tetranucleo‐
tide repeats, have been reported to be unstable in some inherited diseases and in some types
of cancer [23], including head and neck, lung, breast, and bladder cancer [17,23].
The expression levels of the cell cycle-related proteins p21 (CDKN1A), p53 (TP53), cyclin D1
(CCND1), and aurora kinase A (AURKA) may be used as prognostic markers to predict re‐
currence in stage II and stage III colon cancer [24]. In addition, markers of the epithelial–
mesenchymal transition (EMT)–such as reduced expression of keratins, a switch from E-
Cadherin to N-Cadherin, and enhanced migration in D492M cells—might be a useful mark‐
er in breast cancer [25]. Furthermore, expression of the stem cell markers cytokeratins 15 and
19 was altered in squamous cell carcinoma: cytokeratin 15 levels were decreased and the lo‐
calization of cytokeratin 19 was altered [26]. KLK3, which encodes prostate-specific antigen,
a member of the kallikrein family of serine proteases, is a biomarker for prostate cancer de‐
tection and disease monitoring [27,28]. Mitochondrial DNA mutations have been associated
with bladder, head and neck, lung, colorectal, and pancreatic cancer [29-32] (Table 3).
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Highly parallel identification of cancer-related genes using small hairpin RNA screening has
revealed that the expression of known and putative oncogenes, such as EGFR, KRAS, MYC,
BCR-ABL, MYB, CRKL, and CDK4 that are essential for cancer proliferation, is altered in cancer
cells [33]. Other genes such as PTPN1, NF1, SMARCB1, and SMARCE1 have been identified as
essential for the imatinib response of leukemia cells, and TOPOIIA expression is involved in re‐
sistance to etoposide, an anti-topoisomerase II agent, in small cell lung cancer [33-36].
Marker Cancer Type Reference
TP53 mutation
head and neck cancer [18]
bladder cancer [20]
lung cancer (small cell lung cancer and non-small cell lung cancer); breast, colon, esophagus, liver,
bladder, ovary, and brain cancers; sarcomas, lymphomas, and leukemias
[19]
EGFR mutation non-small cell lung cancer [21]
RAS mutation colorectal tumors [22]
DNA microsatellite alterations bladder cancer [23]
alteration in cell cycle mRNA
expression
colon cancer [24]
alteration in cytokeratin mRNA
expression
squamous cell carcinoma [26]
alteration in kallikrein mRNA
expression
prostate cancer [27]
mitochondrial DNA mutations
bladder cancer, head and neck cancer, lung cancer [29]
colorectal tumors [30], [32]
pancreatic cancer [31]
Table 3. Genomic markers of cancer.
2.2. Genes related to cell proliferation
Cyclins,  which regulate  the  cell  cycle,  play important  roles  in  cell  proliferation and the
uncontrolled cell proliferation that is the most important factor in tumorigenesis [37]. Tu‐
mor cells accumulate mutations that result in constitutive mitogenic signaling and defec‐
tive responses to anti-mitogenic signals that contribute to unscheduled proliferation [38].
In  cancer,  unscheduled  proliferation,  genomic  instability,  and  chromosomal  instability
are the three major factors in cell cycle dysregulation [38]. Regulation of the cell cycle is
mainly conducted by complexes of cyclins and cyclin-dependent kinases [38].  Cyclin D1
in cell  migration and proliferation is  temporo-spatially separated by its  biphasic  expres‐
sion induced by thrombin,  a  G protein-coupled receptor  agonist,  which is  mediated by
nuclear  factor  of  activated  T  cells  c1  (NFATC1)  and  signal  transducer  and  activator  of
transcription 3 (STAT3) [39]. Cyclin D1 regulates kinase activity and the G1–S phase tran‐
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sition  in  the  cell  cycle;  deregulated  cyclin  D1  expression  is  well  documented in  breast,
colon,  and prostate  cancers  [39,40].  The  expression of  cyclin  D1 is  regulated by several
factors  including  cytokines  such  as  interleukin  3  and  interleukin  6  via  STAT3  and
STAT5,  or  extracellular  matrix  factors  such  as  collagen,  fibronectin,  and  vitronectin,
which  activate  focal  adhesion  kinase  upon  integrin  clustering,  and  hepatocyte  nuclear
factor 6 [41].  Cyclin D1 is a crucial regulator of Wnt- and Notch-regulated development
[41,42]. The binding of Wnt to its receptor, Frizzled, causes release of β-catenin to trans‐
locate  from  the  cytoplasm  to  the  nucleus,  where  it  forms  a  complex  with  the  ternary
complex  factor  and/or  the  lymphoid  enhancer-binding  factor  [41,43].  Cyclin  D1  is  in‐
duced  by  overexpression  of  β-catenin,  which  is  a  major  component  of  adherens  junc‐
tions  that  link  the  actin  cytoskeleton  to  members  of  the  cadherin  family  of
transmembrane cell–cell adhesion receptors. It  plays an important role in linking the cy‐
toplasmic side of cadherin-mediated cell–cell contacts to the actin cytoskeleton [43]. Beta-
catenin is upregulated in colorectal cancer, which is considered to trigger cyclin D1 gene
expression followed by uncontrolled progression of the cell cycle [43]. In addition, β-cat‐
enin plays another role  in signaling that  involves transactivation,  in complex with tran‐
scription  factors  of  the  lymphoid  enhancing  factor  family  in  the  nucleus  [43].  The
pathway  involving  β-catenin/LEF1  and  elevation  of  cyclin  D1  might  be  crucial  for  tu‐
morigenesis  [43].  Inhibiting  EglN2,  a  member  of  the  EglN  (also  called  PHD  or  HPH)
family of prolyl  hydroxylases that regulates the heterodimeric transcription factor hypo‐
xia-inducible  factor  (HIF),  causes  a  decrease  in  the  expression  of  its  interaction  partner
cyclin D1 in cancer cells and impairs the cells’ ability to proliferate in vivo [44].
Progression  of  the  eukaryotic  cell  cycle  is  driven  by  cyclin-dependent  protein  kinases
(CDKs), which are binding partner of cyclins. The CDK oscillator acts as the primary or‐
ganizer of the cell cycle [45]. Phosphorylation of cyclin-Cdk complexes is one of the pri‐
mary  mechanisms  of  cell  cycle  regulation  [46].  Cyclins  are  degraded  by  ubiquitin-
mediated proteolysis [46]. The ubiquitylation and degradation of cyclin 1 and cyclin 2 are
mediated  by  the  SCF  complex,  a  multi-subunit  ubiquitin  ligase  that  contains  Skp1,  a
member of the cullin family (Cdc53) and an F-box protein, as well as a RING-finger-con‐
taining protein [46]. CDKs including CDK1, CDK2, CDK4, CDK6, and CDK11 have vari‐
ous  functions  that  have  been  investigated  using  loss-of-function,  target  validation,  and
gain-of-function mouse models [38]. CDK1 is a mitotic CDK, also known as cell division
control  protein 2 (CDC2).  It  is  one of  the master regulators of  mitosis  as it  controls  the
centrosome cycle as well as mitotic onset; deficiency in CDK1 results in embryonic lethali‐
ty in the first cell divisions [38,47]. CDK2, CDK4, and CDK6 are interphase CDKs that are
not essential for the mammalian cell cycle; they are, however, required for the prolifera‐
tion of specific cell  types [38].  Deficiency in CDK2, CDK4, and CDK6 caused mid-gesta‐
tion embryonic lethality because of hematopoietic defects [38,47].
2.3. Genes related to cell differentiation
Inhibitor of differentiation 1 (Id1) is associated with the induction of cell proliferation and
invasion [48], as well as the invasive features of cancer and the EMT [48]. The HOX genes
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encode homeodomain-containing transcription factors involved in the regulation of cellular
proliferation and differentiation during embryogenesis [49]. The expression of HOXA1,
which plays an important role in proliferation, apoptosis, adhesion, invasion, the EMT, and
anchorage-independent growth, was significantly increased in oral squamous cell carcino‐
ma compared with in healthy oral mucosa [49], and it might be a useful prognostic marker
for patients with this disease [49].
Wnt/β-catenin signaling controls skeletal development and differentiation [50]. The initiat‐
ing step of skeletal development is mesenchymal condensation, during which mesenchymal
progenitor cells are at least bipotentiate [50]. Osteochondral progenitor cells differentiate in‐
to osteoblasts instead of chondrocytes when Wnt/β-catenin signaling is activated [50]. In vi‐
tro models using human pluripotent stem cell-derived neural progenitor cells have been
used to examine whether G11778A-mutated mitochondrial DNA, which is associated with
Leber’s hereditary optic neuropathy, might be involved in the differentiation of neural pro‐
genitor cells into neurons, oligodendrocytes, and astrocytes [51]. The differentiation of neu‐
ral progenitor cells can be visualized by staining for the neuronal marker class III beta-
tubulin [51]. Alternative splicing of exons play an important role in cellular differentiation
and pathogenesis [52]. Alternative splicing in colorectal cancer and renal cell cancer samples
has been analyzed by the Bioinformatics Exon Array Tool (BEAT, http://beat.ba.itb.cnr.it/)
using an Affymetrix GeneChip Exon Array [52]. When the dataset was analyzed using GO
terms, the cell differentiation (GO:0030154)-related gene delta-like 1 (Drosophila) (DLL1)
was found to be involved in colorectal cancer [52].
2.4. Genes related to apoptosis
Cell  proliferation  and  death  are  regulated  by  various  molecules.  Recently,  microRNAs
have  been  revealed  to  play  important  roles  during  death  receptor-mediated  apoptosis
(programmed  cell  death)  [53].  Transfection  with  miR-133b  caused  a  proapoptotic  effect
on  tumor  necrosis  factor  alpha  (TNFα)-stimulated  HeLa  cells  [53]:  the  expression  of
apoptosis  regulatory  proteins  such  as  transgelin  2  (TAGLN2),  myosin,  heavy  chain  9,
non-muscle  (MYH9),  cytoskeleton-associated  protein  4  (CKAP4),  polypyrimidine  tract
binding  protein  1  (PTBP1),  glutathione-S-transferase  pi  1  (GSTP1),  and  copine  III
(CPNE3)  were  down-regulated  compared  with  in  control  cells  [53].  The  BCL  protein
family  plays  a  major  role  in  regulation  of  the  apoptotic  cascade  [54].  BCL2-associated
protein (BAX) promotes apoptosis and delays disease progression, and has been associat‐
ed  with  longer  disease-free  survival  in  patients  with  a  number  of  gastrointestinal  can‐
cers,  such  as  esophageal,  stomach,  small  intestine,  and  colon  cancer;  moreover,  high
BCL6 expression is  correlated with worse prognosis  in patients  with other gastrointesti‐
nal  tumors,  such  as  esophageal  adenocarcinoma  [54].  There  are  two  major  cell  death
pathways that  transduce the effects  of  various death inducers:  the  extrinsic  death path‐
way that  is  mediated through cell  death  receptors  of  the  TNF receptor  family,  such  as
the  Fas  receptor;  and  the  intrinsic  death  pathway  that  proceeds  through  mitochondria
[55]. The expression of apoptosis signal-regulating kinase (ASK1), which plays an impor‐
tant role as a mitogen-activated protein kinase kinase kinase in apoptosis signaling, is in‐
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creased in  gastric  cancer  [56].  Furthermore,  the  levels  of  cyclin  D1 and phosphorylated
JNK were higher in gastric cancer than in non-tumor epithelium [56].  ASK1 may play a
role in the development of gastric cancer [56].
2.5. Detection of cell proliferation or apoptosis
Several methods have been suggested for the diagnosis of cancer [57]. Protein markers for
cancer include prostate-specific antigen for prostate cancer, CA125 for ovarian cancer, carci‐
noembryonic antigen for colon cancer, human chorionic gonadotropin for trophoblastic can‐
cer, and a-fetoprotein for hepatocellular carcinoma and germ cell tumors [57]. Assays to
detect telomerase activity in clinical samples include the TRAP (telomere repeat amplifica‐
tion protocol) assay, which involves protein extraction and subsequent primer-directed PCR
amplification of telomere extensions [57].
Assays for the detection of kinases that regulate cell growth, proliferation, differentiation,
and metabolism have been developed [58]. The assay technology includes fluorescence po‐
larization to detect protein phosphorylation, scintillation proximity to detect protein de‐
phosphorylation by phosphatases, fluorescence resonance energy transfer to detect protein
cleavage or modification, immunosorbent assays to detect phosphorylation state, luciferase-
based ATP detection to detect the kinase-dependent depletion of ATP, luminescent oxygen
channeling to detect phosphorylation, time-resolved fluorescence resonance energy transfer
to detect phosphopeptide formation, and enzyme fragment complementation to detect mo‐
lecular interactions with kinases [58,59]. Cell proliferation can also be determined by the tet‐
razolium hydroxide (XTT) cell proliferation assay, in which absorbance is measured by an
ELISA reader under 490-nm-wavelength light (Biological Industries) [60].
Cell proliferation assays and apoptosis assays have been used to examine the effects of in‐
hibitors on cancer cells [61]. The cell proliferation of Neuro-2A cells, neuroblastoma cells,
can be determined using the CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay
reagent (Promega) [61]. A colony formation assay using Neuro-2A cells was used to deter‐
mine the effect of an inhibitor of GSK-3β [61]. In this experiment, colonies were allowed to
form for 10 days, after which the cells were fixed with 70% ethanol and stained with 1%
methylene blue. Apoptosis was then measured by flow cytometry using an Annexin V-allo‐
phycocyanin (APC) /propidium iodide (PI) detection kit (BD PharMingen) [61]. Apoptosis
was also determined using 4’6-diamidino-2-phenylindole (DAPI) staining, observing apop‐
totic nuclear morphology, and immunoblotting with antibodies to β-catenin, X-linked inhib‐
itor of apoptosis, and BCL2 [61]. Cell cycle analysis using PI to quantify the proportions of
cells in the G1/G0 or G2–M phases was used to examine cell cycle status [61].
Viable cells can be determined using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoli‐
um bromide) colorimetric assays [62]. Absorbance at 570 nm is used to detect the incorporation
of MTT. Apoptosis can also be determined by caspase activation using an anti-poly ADP-ri‐
bose polymerase (PARP) antibody [62]. Viable cells can also be determined using a 3-(4,5-di‐
methyl-thiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium  (MTS)
kit (Promega) [63]. The terminal transferase dUTP nick end labeling (TUNEL) assay is com‐
monly used to detect apoptosis [63]. Harvested cells are resuspended in DNA labeling solution
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consisting of TdT reaction buffer, TdT enzyme, and BrdUTP, then stained with PI to detect a
fluorescein isothiocyanate-labeled anti-BrdU antibody [63]. Cell viability and proliferation as‐
says were used to validate internal tandem duplication mutations in FLT3 as a therapeutic tar‐
get for human acute myeloid leukemia [64]. Cell viability and proliferation can be determined
using a Vi-cell XR automated cell viability analyzer (Beckman Coulter) [64].
3. Genomic variation in disease
3.1. Genome-wide association studies in cancer
Despite extensive research efforts for several decades, the genetic basis of common human
diseases such as cancers remains largely unknown [65]. Genome-wide association studies
(GWAS) have emerged as an important tool for the discovery of genomic regions that har‐
bor genetic variants conferring risk for various cancers [66,67]. Family-based linkage studies
and studies comprising tens of thousands of gene-based SNPs can also assay genetic varia‐
tion across the genome [68], but the National Institutes of Health guidelines for GWAS re‐
quire a sufficient density of genetic markers to capture a large proportion of the common
variants in the study population, measured in enough individuals to provide sufficient pow‐
er to detect variants of modest effect [67]. The recent success of GWAS can be attributed to
the convergence of new technologies that can genotype hundreds of thousands of SNPs in
hundreds or thousands of samples [66,69].
GWAS have been conducted in the five of the most common cancer types: breast, prostate,
colorectal, lung, and melanoma (Table 4) and have identified more than 20 novel disease lo‐
ci, confirming that susceptibility to these diseases is polygenic [70]. For many years, human
genetics has been used to map rare mutations with large effect sizes in families or genetical‐
ly homogeneous populations, such as BRCA1/BRCA2 mutations in Ashkenazi women with
breast cancer and ovarian cancer [71]. A number of SNPs have now been associated with
breast cancer; for example, a SNP in intron 2 of the FGFR2 gene, which encodes a receptor
tyrosine kinase that is amplified and overexpressed in 5–10% of breast tumors [72,73], and
SNPs on chromosomes 16q and 5q. The locus on 16q contains a gene TNRC9 and a hypothet‐
ical gene LOC643714. The function of TNRC9 is unknown but the presence of an HMG box
motif suggests that it might act as a transcription factor. The 5q locus includes MAP3K1,
which encodes a protein involved in signal transduction (but not previously known to be
involved in cancer) and two other genes: MGC33648 and MIER3. In addition, several of the
breast cancer loci appear to be associated with specific subtypes of the disease. In particular,
the FGFR2 association is strongly associated with estrogen receptor-positive breast cancer,
while the TNRC9 SNP is associated with both estrogen receptor-positive and -negative
breast cancer [74,75]. It is surprising that none of the strongest associations map to regions
harboring estrogen/progesterone genes in women of European background, particularly be‐
cause a GWAS in Asian women reported a convincing association with markers near the es‐
trogen receptor alpha (ESR1) gene [76]. In prostate cancer, the first and most important
region to emerge was 8q24. This region was first associated with prostate cancer through
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linkage studies by the deCode group, was followed up by association analyses [77], and has
been confirmed in subsequent GWAS [78-81]. Another signal, on chromosome 10q13, points
to a variant in the promoter of the MSMB gene, which encodes the PSP94 protein; this is
now under intense investigation as a biomarker for prostate cancer [80,81].
In general, the susceptibility alleles discovered thus far are common—that is, with a fre‐
quency in one or more population of >10%, and each allele confers a small contribution to
the overall risk of the disease. For nearly all regions conclusively identified by GWAS, the
effect sizes per allele are estimated at <1.3. It was not anticipated that GWAS in certain can‐
cers would yield many novel regions when other cancers strongly associated with particular
environmental exposures have yielded so few regions. For example, prostate cancer, breast
cancer, and colon cancer have been associated with 29, 13, and 10 regions of the genome,
respectively, while there are only three associated regions for lung cancer in smokers, and
three for bladder cancer despite analysis of sufficiently large data sets [67]. Several GWAS
for lung cancer have identified the same locus on 15q25, suggesting that this is an important
susceptibility locus for this disease [82-87]. This locus contains the nicotinic acetylcholine re‐
ceptor subunit genes CHRNA3 and CHRNA5, suggesting that susceptibility may be mediat‐
ed through smoking behavior [86,87].
GWAS represent an important advance in discovering genetic variants influencing disease
but have important limitations. There is a high potential for false-positive results, they do
not  yield  information  on  gene  function,  they  are  insensitive  to  rare  and structural  var‐
iants, they require large sample sizes, and incur possible biases because of case and con‐
trol  selection  and genotyping  errors  [88].  Clinicians  and scientists  must  understand the
unique  aspects  of  these  studies  and  be  able  to  assess  and  interpret  GWAS  results  for
themselves and their patients. However, at present these studies mainly represent a val‐
uable  discovery  tool  for  examining  genomic  function  and  clarifying  pathophysiological
mechanisms.  However,  through  GWAS,  the  identification  of  variants,  genes,  and  path‐
ways involved in multiple cancers offers a potential route to new therapies, improved di‐
agnosis, and better disease prevention [65].
Cancer
type
ReferenceYear Platform
[SNP passing
QC]
Ethnic
group
Initial sample size Replication sample size
Cases Controls Ethnic
groups
Cases Controls
Breast cancer [89] 2012 Affymetrix
[555,525]
Korean 2,273 2,052 Korean 4,049 3,845
[90] 2012 Affymetrix
[690,947]
Chinese 2,918 2,324 Chinese 6,838 6,888
Han Chinese 1,297 1,585
Taiwan Chinese 1,066 1,065
Korean 5,038 6,869
Japanese 1,934 1,875
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Cancer
type
ReferenceYear Platform
[SNP passing
QC]
Ethnic
group
Initial sample size Replication sample size
Cases Controls Ethnic
groups
Cases Controls
[91] 2012 Affymetrix
[613,031]
Chinese 1,950 - Chinese 4,160 -
[92] 2012 Illumina
[470,796]
Japanese 240 - Japanese 222 -
[93] 2011 Affymetrix
[684,457]
East Asian 2,062 2,066 East Asians 15,091 14,877
[94] 2011 Affymetrix
[782,838]
European 302 321 European 1,153 1,215
[95] 2011 Illumina
[~296,114]
British 1,694 2,365 British 7,317 8,124
European 1,145 1,142
[96] 2010 Illumina
[285,984]
Swedish & Finnish 617 4,583 European 1,001 7,604
[97] 2010 Affymetrix
[592,163]
European 899 804 European 1,264 1,222
[98] 2010 Illumina
[285,984]
European 2,702 5,726 European 7,386 7,576
[99] 2010 Illumina
[582,886]
UK 3,659 4,897 European 12,576 12,223
[100] 2010 Illumina
[528,252]
British 1,145 - British 4,335 -
[101] 2009 Illumina
[528,173]
1,145 1,142 8,625 9,657
[102] 2009 Affymetrix
[up to 607,728]
Chinese 1,505 1,522 Chinese 1,554 1,576
[103] 2008 Affymetrix
[200,220]
30 30 - - -
[104] 2008 Affymetrix
[492,900]
Ashkenazi Jewish 249 299 Ashkenazi
Jewish
1,193 1,166
[105] 2007 Affymetrix
[70,897]
Framing-ham 1,345 - - - -
[106] 2007 Perlegen
[205,586]
390 634 26,646 24,889
[107] 2007 Illumina
[528,173]
1,145 1,142 1,176 2,072
The Investigation of Gene Regulation and Variation in Human Cancers and Other Diseases
http://dx.doi.org/10.5772/51271
445
Cancer
type
ReferenceYear Platform
[SNP passing
QC]
Ethnic
group
Initial sample size Replication sample size
Cases Controls Ethnic
groups
Cases Controls
Prostate cancer [108] 2012 Illumina
[509,916]
European 1,176 1,101 European 1,964 3,172
[109] 2012 Affymetrix
& Illumina
[1,117,531]
(imputed)
4,723 4,792 - - -
[110] 2011 NR
[2.6 million]
(imputed)
European 6,621 6,939 European
Japanese
Chinese
African
American
22,957
285
135
112
7,140
23,234
298
135
298
5,455
[111] 2011 Illumina
[571,243]
European 2,782 4,458 European 8,217 6,732
[112] 2011 Illumina
[1,047,198]
African American 3,425 3,290 African
American
Senegalese
Ghanaian
Barbadian
1,275
86
271
246
1,695
414
968
253
[113] 2011 Affymetrix
[387,384]
European 202 100 European 1,122 1,167
[114] 2010 Affymetrix
[419,613]
Caucasian 222 415 Caucasian 500 155
[115] 2010 Illumina
[510,687]
Japanese 1,583 3,386 Japanese 3,001 5,415
[116] 2009 Illumina
[541,129]
European 1,854 1,894 European,
Chinese,
Japanese,
African
American,
Latino, and
Hawaiian
19,879 18,761
[117] 2009 Illumina
[310,520]
Icelandic 1,968 35,382 European 11,806 12,387
[118] 2008 Illumina
[541,129]
European 1,854 1,894 3,268 3,366
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Cancer
type
ReferenceYear Platform
[SNP passing
QC]
Ethnic
group
Initial sample size Replication sample size
Cases Controls Ethnic
groups
Cases Controls
[119] 2008 Illumina
[527,869]
1,172 1,157 3,941 3,964
[120] 2007 Affymetrix &
Illumina
[60,275]
1,235 1,599 1,242 917
[121] 2007 Affymetrix
[70,897]
Framingham 1,345 - - -
[122] 2007 Illumina
[316,515]
1,453 3,064 East Asia 1,210 2,445
[123] 2007 Illumina
[538,548]
1,172 1,157 3,124 3,142
Colorectal cancer[124] 2011 Illumina
[378,739]
European 2,906 3,416 European 8,161 9,101
[125] 2010 Illumina
[~550,000]
(imputed)
European 3,334 4,628 European 14,851 15,569
[126] 2010 Affymetrix
[460,945]
German 371 1,263 German
Czech
4,121
794
7,344
815
[127] 2008 Illumina
[~548,586]
1,902 1,929 4,878 4,914
[128] 2008 Illumina
[541,628]
981 1,002 16,476 15,351
[129] 2008 Illumina
[547,647]
922 927 17,872 17,526
[130] 2007 Illumina
[547,647]
940 965 7,473 5,984
[131] 2007 Illumina
[547,647]
930 960 7,334 5,246
[132] 2007 Affymetrix &
Illumina
[99,632]
1,257 1,336 6,223 6,443
Lung
cancer
[133] 2011 Affymetrix
[906,703]
Chinese 2,331 3,077 Chinese 6,313 6,409
[134] 2011 Illumina
[307,260]
White 327 European 587
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Cancer
type
ReferenceYear Platform
[SNP passing
QC]
Ethnic
group
Initial sample size Replication sample size
Cases Controls Ethnic
groups
Cases Controls
[135] 2011 Illumina
[620,901]
(pooled)
Italian 600 - Italian 317 -
[136] 2010 Affymetrix
[265,996]
Han Chinese 245 - Han Chinese 305 -
[137] 2010 Affymetrix
[246,758]
Korean 621 1,541 Korean 804 1,470
[138] 2010 Illumina
[542,050]
377 377 511 1,007
[139] 2009 Illumina
[515,922]
European 5,739 5,848 European 7,561 13,818
[140] 2009 Illumina
[511,919]
European 1,952 1,438 European 5,608 6,767
[141] 2008 Illumina
[317,498]
1,154 1,138 2,724 3,694
[142] 2008 Illumina
[306,207]
10,995
smokers
4,848 smokers
[143] 2008 Illumina
[310,023]
1,926 2,522 2,513 4,752
[144] 2007 Affymetrix
[~116,204]
(pooled)
Italian 338 335 Norwegian 265 356
Melanoma [145] 2011 Illumina
[594,997]
European 2,804 7,618 European 5,551 7,449
[146] 2011 Illumina
[5,480,804
(imputed)]
European 2,168 4,387 European 5,193 15,144
[147] 2011 Illumina
[818,977]
European 1,804 1,026 European 6,483 23,324
[148] 2011 Illumina
[491,227]
European 156 2,150 NR - -
[149] 2009 Illumina
[~317,000]
European 1,539 3,917 European 2,312 1,867
Table 4. Summary of GWAS for the five of the most common types of cancer.
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3.2. Genetic risk score in cancer and diabetes
Type 2 diabetes mellitus and cancers are major health problems worldwide [150,151]. The
recent increase in the prevalence of these diseases is largely attributable to environmental
factors. However, convincing evidence shows that genetic factors may play an important
role in these diseases [152,153]. Recent GWAS have led to the identification of a series of
SNPs that are robustly associated with either the risk of diabetes or cancers [151,154-159].
For type 2 diabetes mellitus, common SNPs have been identified in the PPARG, KCNJ11,
and TCF7L2 genes, and have been widely replicated in populations of various ethnicities
[160-162]. Other potential new loci include HHEX, CDKAL1, CDKN2A/B, IGF2BP2, SLC30A8,
and WFS1 [65,155-159,163,164]. A number of SNPs have been identified as associated with
breast cancer risk, including FGFR2, CASP8, ERBB4, TAB2, BARX2, TMEM45B, ESR1,
FGFR2, TNRC9, MAP3K1, MGC33648, MIER3, and RAD51L1 [74,75,151] (Table 5).
Combining multiple loci with modest effects into a global genetic risk score (GRS) might im‐
prove the identification of those at risk for common complex diseases such as type 2 diabe‐
tes and cancers [165-167]. Several studies have developed methods to predict the risk of
certain diseases, such as coronary heart disease, type 2 diabetes, and breast cancer, aggregat‐
ing information from multiple SNPs into a single GRS [151,168,169]. For example, in the
Atherosclerosis Risk in Communities study, the aggregation of multiple SNPs into a single
GRS was responsible for improving the prediction of coronary heart disease incidence [168].
In a study that used a GRS to determine the risk of type 2 diabetes in US men and women,
individuals in the highest quintile of GRS had a significantly increased risk of type 2 diabe‐
tes compared with those in the lowest quintile; however, the addition of a GRS to the con‐
ventional model consisting of lifestyle risk factors only increased the area under the curve
by only 1% (AUC=0.78). In this instance, the GRS was determined to be useful only when
combined with the body mass index or a family history of diabetes [169]. For breast cancer, a
GRS was created using 14 SNPs previously associated with breast cancer, and was substan‐
tially more predictive of estrogen receptor-positive breast cancer than of estrogen receptor-
negative breast cancer, particularly for absolute risk [151]. Further studies are needed to
confirm whether a GRS improves disease risk prediction.
The GRS is calculated on the basis of reproducible tagging of SNP-associated loci reaching
genome-wide levels of significance. The GRS can be created by two methods: a simple count
method (count GRS) and a weighted method (weighted GRS) [169,170]. Both methods antic‐
ipate each SNP to be independently associated with risk. An additive genetic model is used
for each SNP, applying a linear weighting of 0, 1, or 2 to genotypes containing 0, 1, or 2 risk
alleles, respectively. This model is known to perform well even when the true genetic model
is unknown or wrongly specified [171]. The count model assumes that each SNP in the pan‐
el contributes equally to the disease risk and is calculated by summing the values for each of
the SNPs. The weighted GRS is calculated by multiplying each B-coefficient, the estimates
resulting from an analysis carried out on variables that have been standardized, by the num‐
ber of corresponding risk alleles (0, 1, or 2).
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Disease Reference Year Ethnic group Participants No. of SNPs Genes found from GWAS
Type 2
diabetes
[165] 2008 Framingham 2,377 diabetic patients 18 NOTCH2 (rs10923931),
BCL11A (rs10490072),
THADA (rs7578597),
IGF2BP2 (rs1470579),
PPARg (rs1801282),
ADAMTS9 (rs4607103),
CDKAL (rs7754840),
VEGFA (rs9472138),
JAZF1 (rs86475),
SLC30A8 (rs13266634),
CDKNA/2B (rs10811661),
HHEX (rs1111875),
CDC123, CAMK1D (rs12779790),
TCF7L2 (rs7903146),
KCNJ11 (rs5219), INS (rs689),
DCD (rs1153188),
TSPAN8, LGR5 (rs7961581)
[169] 2009 European 2,809 diabetic
patients &
3,501 health
controls
10 WFS1 (rs10010131),
HHEX (rs1111875),
CDKAL1 (rs7756992),
IGF2BP2 (rs4402960),
SLC30A8 (rs13266634),
CDKN2A/B (rs10811661),
TCF7L2 (rs12255372),
PPARG (rs1801282),
KCNJ11 (rs5219)
Breast cancer [151] 2010 UK 10,306
breast cancer
patients &
10,393 controls
14 FGFR2 (rs2981582),
TNRC9 (rs3803662),
2q35 (rs13387042),
MAP3K1 (rs889312),
8q24 (rs13281615),
2p (rs4666451),
5pas (rs981782),
CASP8 (rs104548),
LSP1 (rs3817198),
5p (rs30099),
TGFB1 (rs198/2073),
ATM (rs1800054),
TNRC9 (rs8051542),
TNRC9 (rs12443621)
Table 5. Studies using a genetic risk score for cancers and diabetes, comprising SNPs identified in GWAS.
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3.3. Cancer Cell Line Encyclopedia
The Cancer Cell Line Encyclopedia (CCLE) has made predictive modeling of anticancer
drug sensitivity a realistic proposition, by determining genomic markers of drug sensitivity
in cancer cells [172,173]. The CCLE contains information from 947 human cancer cell lines
including data on gene expression, chromosomal copy number, and massively parallel se‐
quencing data. It has been used to identify genetic, lineage-specific, and gene expression-
based predictors of drug sensitivity [172]. This has revealed, for example, that the plasma
cell lineage is correlated with sensitivity to IGF1 receptor inhibitors, aryl hydrocarbon recep‐
tor (AHR) expression is associated with MEK inhibitor efficacy in NRAS-mutant lines, and
SLFN11 expression is associated with sensitivity to topoisomerase inhibitors [172]. Genomic
markers of drug sensitivity in cancer cells have also been systematically identified using the
Genomics of Drug Sensitivity in Cancer database (http://www.cancerRxgene.org) [173].
These databases will enable to overview genome quality.
4. Conclusion
There are dramatic changes in the genomes of cancer cells, which vary according to cancer
subtype. Integrative and wide investigations of cancer cell genomes have revealed muta‐
tions and alterations in gene expression that are associated with the disease. Databases that
include abundant data related to gene and protein conformation, gene expression, and ge‐
nomic mutations enable the construction of dynamic cellular simulations and disease mod‐
els. New sequencing tools such as next-generation sequencing will reveal new horizons in
the prediction of disease and drug sensitivity, which play an important role in personalized
medicine. Appropriate translation of the abundance of information to clinical practice is one
of most important future challenges for medicine. The quality of genome would be one of
the important factors for detecting the development of the disease.
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